Sandoz AG expands reach of adalimumab biosimilar in US through commercialization agreement with Cordavis

I’m excited to share that Sandoz has an agreement with CVS Health’s newly established subsidiary Cordavis to help bring biosimilar medicines to more patients in the US under Cordavis private-label. Through Cordavis, CVS Health is developing a portfolio of products that facilitate broader access to biosimilars and drive sustainability for the US healthcare system – and Sandoz is proud to unite in this effort, in addition to its own commercialization efforts. This is the result of a shared commitment to lowering healthcare costs and ensuring patients can sustainably and affordably access the biologic medicines they need. This agreement advances the Sandoz mission of #PioneeringAccessForPatinets. Read our press release here: 

Keren Haruvi

President North America, Sandoz Inc.